Scholar Rock shares: TD Cowen keeps buy on FDA approval, broad label

Scholar Rock received FDA approval for Isembyld (apitegromab) for spinal muscular atrophy patients aged 2 and older on SMN2 treatment, with a broad label that has no ambulatory-status, SMA-subtype, or treatment-duration restrictions. Isembyld carries an annual gross wholesale acquisition cost of about $420,000 for an average 40kg patient; TD Cowen forecasts $2 million of U.S. sales in Q4 2026 and $2.3 billion in peak U.S. sales by 2035. TD Cowen maintained its Buy rating and $71 target, implying 34% upside from $53.06, while Truist and BMO set $76 targets and Raymond James set a $72 target.

Analysis

SRRK has moved from binary regulatory risk to an execution-and-access story, which usually shifts valuation from probability-adjusted pipeline NPV toward the credibility of launch curves. The broad eligible population supports a larger theoretical addressable market, but realized revenue will be constrained initially by payer prior authorization, infusion-center capacity, and whether prescribers use the product on top of—rather than in place of—established SMA regimens. The key near-term variable is not label breadth but the conversion rate from treated patients to reimbursed starts.

Consensus targets appear to embed substantial long-duration penetration before launch evidence exists. At a premium biologic price, even modest gross-to-net discounts, discontinuation, or slower community-site adoption can materially defer cash flows; a one-to-two-year delay in reaching meaningful sales would have an outsized effect on DCF value for a company whose core thesis is concentrated in one asset. Manufacturing redundancy is strategically positive, but dual-site qualification and supply reliability remain a commercial gating item rather than a resolved risk.

Over the next days, the approval removes a major short catalyst and raises sell-the-news risk after the stock’s strong run. Over 1-3 months, formulary placements, launch commentary, first patient starts, and any disclosure on gross-to-net assumptions should determine whether the premium holds. Over 6-18 months, the more consequential competitive question is whether incremental functional benefit is sufficiently visible to persuade payers to fund combination treatment; if not, SRRK may compete for budget with Biogen's Spinraza and Roche's Evrysdi rather than expand category spend.

The contrarian view is that bullish physician-intent surveys overstate paid utilization in ultra-rare disease markets, where medical necessity criteria are set by payers, not prescribers. Conversely, upside to current expectations emerges if combination use becomes standard rapidly and the company demonstrates low abandonment with durable functional outcomes; that would justify further multiple expansion despite a currently demanding valuation.

Key Decisions for Investors

• Do not chase SRRK immediately following approval; use a 4-8 week post-launch watch period. Initiate only if early access commentary confirms broad payer coverage and management can support a credible 2027 net-sales trajectory; a 20-25% pullback without deterioration in access data would offer better asymmetric entry.
• For event-driven exposure, prefer a defined-risk SRRK call spread 6-12 months out rather than outright shares, sized small. The thesis requires evidence of rapid uptake; cap loss at premium because launch friction or an equity raise can compress the stock sharply even with an approved product.
• Set a downside thesis trigger if first two quarterly launch updates show delayed reimbursement, high gross-to-net discounting, supply constraints, or management reduces early patient-start expectations. Those signals would challenge peak-sales timing and support exiting longs or tactically shorting against a biotech ETF hedge.
• Monitor BIIB and RHHBY for category-spend pressure rather than assuming direct displacement. Evidence that Isembyld is funded primarily as add-on therapy is modestly positive for SMA franchise durability; payer-mandated sequencing or switching would create greater competitive risk for incumbents but is not yet established.